Weighing Borderline Resectability, Neoadjuvant vs Perioperative Immunotherapy, and Targeted Therapy in Early-Stage NSCLC

During an OncLive^® State of the Science Summit™ on lung cancer held October 14, 2026, in New Haven, Connecticut, and chaired by Sarah Goldberg, MD, MPH, of Yale School of Medicine, a panel led by Gavitt Woodard, MD, discussed perioperative treatment strategies in early-stage non–small cell lung cancer (NSCLC), including borderline resectable disease, neoadjuvant chemoimmunotherapy, perioperative immunotherapy regimens, and targeted therapy for EGFR-mutant disease.